




Injectable HIV Medications: Apretude and Cabenuva

Ghada Ayad, PharmD | PGY-1 Community -Based
Pharmacy Resident at ACME Sav -ON
Desiree Surplus, PharmD, AAHIVP



Agenda

APRETUDE

Overview of Apretude for HIV -1 PrEP

CABENUVA

Overview of Cabenuva for HIV -1 Treatment

OTHER INJECTABLE HIV MEDICATIONS IN TRIAL


Discussion of other injectable HIV medications that are in clinical trials

01

APRETUDE



What is Apretude?



- Brand Name: Apretude
 - Generic: Cabotegravir
- Indication: **PrEP to reduce the risk of HIV infection**
 - Adults and adolescents
 - Must have a negative HIV test before use
- Gluteal intramuscular (IM) injection
- Contraindications
 - Unknown HIV status or positive HIV status
 - History of allergic reaction to cabotegravir
 - Coadministration with drugs that can prevent Apretude from working



Apretude: Dosing Schedule

Prior to Initiation


Optional: Start 1 month of oral cabotegravir 30mg to assess tolerability

Initiation

Single 600 -mg 3mL injection given 1 month apart for 2 consecutive months on the last day of an oral lead -in if used or within 3 days

Maintenance

One injection every 2 months; 6 injections every year



Missed Doses: Planned

- Oral **cabotegravir 30 mg** for 2 months to replace 1 missed injection
- Repeat Apretude on the last day of oral therapy or within 3 days
- Oral PrEP greater than 2 months: An alternative oral regimen is recommended

Missed Doses: Unplanned



Time since Last Injection	Recommendation
If second injection is missed and time since first injection is:	
Less than or equal to 2 months	Administer 600-mg (3-mL) gluteal intramuscular injection of APRETUDE as soon as possible, then continue to follow the every-2-month injection dosing schedule.
Greater than 2 months	Restart with 600-mg (3-mL) gluteal intramuscular injection of APRETUDE, followed by a second 600-mg (3-mL) initiation injection dose 1 month later. Then continue to follow the every-2-month injection dosing schedule thereafter.
If third or subsequent injection is missed and time since prior injection is:	
Less than or equal to 3 months	Administer 600-mg (3-mL) intramuscular injection of APRETUDE as soon as possible, then continue with the every-2-month injection dosing schedule.
Greater than 3 months	Restart with 600-mg (3-mL) gluteal intramuscular injection of APRETUDE, followed by the second 600-mg (3-mL) initiation injection dose 1 month later. Then continue with the every-2-month injection dosing schedule thereafter.

How long does Apretude stay in the body?

- Apretude can remain up to 12 months or longer after the last injection
 - Half life elimination: 5.6 -11.5 weeks



Drug Interactions



Anticonvulsants

- Carbamazepine, Oxcarbazepine, Phenobarbital, Phenytoin
- **Avoid Combination**



Antimycobacterials

- Rifampin, Rifapentine
- **Avoid Combination**



Antimycobacterials

- Rifabutin
- Can use concurrently, increased dosing frequency for Aprelude



Apretude Adverse Effects

- Common side effects
 - Inject site reactions
 - Diarrhea
 - Headache
 - Pyrexia
 - Fatigue
- Hepatotoxicity
 - Monitoring: Liver function tests
- Monitor
 - Depressive symptoms
 - Hypersensitivity reactions




Cabenuva

02



What is Cabenuva?



- Brand Name: Cabenuva
 - Generic: Cabotegravir and Rilpivirine
- Indication: **Treatment of HIV -1 infection**
 - Can be used in adults and adolescents
- Long-Acting Injectable
 - Gluteal intramuscular (IM) injection
- Contraindications
 - History of allergic reaction to cabotegravir or rilpivirine
 - Coadministration with drugs that can prevent Cabenuva from working



Cabenuva: Dosing Schedule

Prior to Initiation

Optional: 1-month of oral cabotegravir 30mg and rilpivirine 25mg, taken with a meal; used to assess tolerability

Initiation

Cabenuva 600mg - 900mg injection on the last day of current antiretroviral therapy or oral lead-in
Note: 2 consecutive months of initiation for every 2 months dosing

Maintenance

- **Monthly:** Cabenuva 400mg - 600mg injection
- **Every 2 months:** Cabenuva 600mg - 900mg injection

Missed Doses: Planned

- Oral: Cabotegravir 30mg and rilpivirine 25mg once daily
 - Up to 2 months to replace missed injection visits
- For durations greater than 2 months, an alternative oral regimen is recommended

Missed Dose: Unplanned Monthly

Time since Last Injection	Recommendation
Less than or equal to 2 months	Resume with 400-mg (2-mL) cabotegravir and 600-mg (2-mL) rilpivirine gluteal intramuscular monthly injections as soon as possible.
Greater than 2 months	Re-initiate the patient with 600-mg (3-mL) cabotegravir and 900-mg (3-mL) rilpivirine gluteal intramuscular injections then continue to follow the 400-mg (2-mL) cabotegravir and 600-mg (2-mL) rilpivirine gluteal intramuscular monthly injection dosing schedule.

Missed Dose: Unplanned Every 2 Months



Missed Injection Visit	Time since Last Injection	Recommendation
Injection 2 (Month 2)	Less than or equal to 2 months	Resume with 600-mg (3-mL) cabotegravir and 900-mg (3-mL) rilpivirine intramuscular injections as soon as possible, then continue to follow the every-2-month injection dosing schedule.
	Greater than 2 months	Re-initiate the patient with 600-mg (3-mL) cabotegravir and 900-mg (3-mL) rilpivirine intramuscular injections, followed by the second initiation injection dose 1 month later. Then continue to follow the every-2-month injection dosing schedule thereafter.
Injection 3 or later (Month 4 onwards)	Less than or equal to 3 months	Resume with 600-mg (3-mL) cabotegravir and 900-mg (3-mL) rilpivirine intramuscular injections as soon as possible and continue with the every-2-month injection dosing schedule.
	Greater than 3 months	Re-initiate the patient with 600-mg (3-mL) cabotegravir and 900-mg (3-mL) rilpivirine intramuscular injections, followed by the second initiation injection dose 1 month later. Then continue with the every-2-month injection dosing schedule thereafter.

How long does Cabenuva stay in the body?

- Cabenuva can remain in the body for up to 12 months or longer
 - Half -life elimination - Cabotegravir: 5.6 -11.5 weeks, Rilpivirine : 13 to 28 weeks



Drug Interactions



Anticonvulsants

- Carbamazepine, Oxcarbazepine, Phenobarbital, Phenytoin
 - **Avoid Combination**



Antimicrobials

- Rifampin, Rifampentine
- Rifabutin
 - **Avoid Combination**



Glucocorticoid & Herbs

- Dexamethasone (more than one single dose)
- St John's Wort
 - **Avoid Combination**





Cabenuva Adverse Effects

- Common side effects rilvipirine
 - Inject site reactions
 - Dyspnea
 - Bronchospasm
 - Agitation
- Hepatotoxicity
 - Monitoring: Liver function tests
- Monitor
 - Depressive symptoms
 - Hypersensitivity reactions



03

In Clinical Trials



Sunlenca

- Generic name: Lenacapivir
- Indication: Treatment of HIV -1 in pts with multi - drug resistance
 - FDA Approved in December 2022
 - After starting dose, Sunlenca is given subcutaneous (SQ) injection every **6 months**
- Lenacapivir is in clinical trial in Europe to test the efficacy in HIV PrEP

Trogarzo

- Generic name: Ibaluzimab , monoclonal antibody
- Indication: Treatment of HIV -1 in pts with multi - drug resistance
 - Currently in Phase 3 trial
 - Long -acting IM injection

Thank You!

DO YOU HAVE ANY
QUESTIONS?


ghada.ayad@albertsons.com

CREDITS: This presentation template was created
by **Slidesgo**, and includes icons by **Flaticon** and
infographics & images by **Freepik**





RESOURCES



1. [Home | APRETUDE \(cabotegravir 200 mg/mL\) Official HCP Website \(apretudehcp.com\)](#)
 2. [Home | CABENUVA Official HCP Website \(cabenuvahcp.com\)](#)
 3. Lexicomp
- 

